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The proteasome, which mediates the ubiquitin-dependent
degradation of intracellular proteins, is well recognized as an
important anticancer target (Figure 1). So far, three inhibitors
of this multiprotease complex have received FDA approval for
treating multiple myeloma: the peptide boronic acids borte-
zomib and ixazomib and the peptide epoxyketone carfilzo-
mib.[1] Several other proteasome inhibitors have entered clini-
cal trials, including the peptide boronic acid delanzomib and
the peptide epoxyketone oprozomib.[2]
Although the FDA-approved proteasome inhibitors have
achieved major breakthroughs in treating multiple myeloma,
they have shown limited efficacy in treating most other types
of cancer. This and other limitations, including severe side ef-
fects and inevitable drug resistance, continue to fuel the quest
for new proteasome inhibitors that exhibit improved safety
and efficacy profiles in and beyond multiple myeloma. Gaining
a detailed understanding of the structural features of protea-
somes and of the molecular interactions of existing inhibitors
with the proteasome’s active sites is a crucial step towards de-
signing inhibitors that meet these criteria.
Crystallographic studies have provided a wealth of informa-
tion on proteasome structure and function. Since these studies
began in the 1990s, researchers have solved the crystal struc-
tures of proteasome core complexes derived from yeast,
bovine, murine, and, most recently, human cells.[3] The 20S
core complexes of these disparate species have strikingly simi-
lar structures. Their cylindrical shapes are built of four axially
stacked heptameric rings. Each of the two inner rings contains
three catalytically active subunits—b1, b2, and b5—whose
active sites are sequestered within the complex’s interior.[3a]
The proteasome’s catalytic subunits are members of the N-ter-
minal nucleophile (Ntn) hydrolase family, unlike most other
proteases in mammalian cells (Figure 1).[4]
In addition, the crystal structures of 20S proteasomes in
complex with peptide boronic acid or peptide epoxyketone in-
hibitors have helped explain how these inhibitors interact with
the proteasome’s active sites.[3c, d, 5] The structure of the borte-
zomib-bound yeast proteasome revealed that, as expected, the
boron atom of bortezomib’s boronic acid pharmacophore
reacts with the g oxygen atom of the proteasome’s catalytic
threonine residue to form a stable, yet reversible, tetrahedral
adduct.[5a] Conversely, based on the structure of the yeast pro-
teasome complexed with the natural product peptide epoxy-
ketone inhibitor epoxomicin, Groll et al. concluded that the re-
action of this inhibitor with the catalytic threonine forms a six-
membered morpholino ring.[5b] They proposed that the forma-
tion of this six-membered ring occurs in two steps: an initial
step in which the catalytic threonine’s g oxygen atom attacks
the epoxyketone pharmacophore’s carbonyl group to form
a hemiketal, and a second step in which the catalytic threo-
nine’s N-terminal amino group attacks the epoxide a carbon
to form the irreversible morpholino adduct (Figure 2). The re-
quirement for the N-terminal amino group—in addition to the
side-chain nucleophile—of the catalytic threonine residue for
forming this adduct appeared to explain the exquisite specifici-
ty of peptide epoxyketones for proteasomes over non-protea-
somal proteases.[5b]
In a recent Science article, Schrader et al. enhance our knowl-
edge of the proteasome’s active sites, and of how these sites
interact with peptide boronic acid and peptide epoxyketone
Figure 1. The ubiquitin–proteasome pathway for protein degradation. A
series of three enzymes—E1, E2, and E3—assemble a polyubiquitin chain on
a substrate protein to mark it for degradation by the proteasome. The poly-
ubiquitin chain is recognized by the proteasome’s 19S regulatory cap, which
removes the chain and feeds the protein into the 20S proteasome core.
Each of the two outer rings of the 20S core contains seven a subunits (a1–
a7), while each of the two inner rings contains seven b subunits (b1–b7).
Only b1, b2, and b5 are catalytically active; they contain active sites harbor-
ing catalytic N-terminal threonine (Thr1) residues. These three subunits work
together to degrade the incoming protein to short peptides.
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inhibitors. Using an optimized protocol, they solved the struc-
tures of 20S proteasomes from human HeLa cervical carcinoma
cells at an unprecedented 1.8 a resolution—a considerable im-
provement over the 2.6 a structure of the human erythrocyte
20S proteasome reported previously.[3d, 6] They also acquired
high-resolution cocrystal structures of human 20S proteasomes
with six different inhibitors, including the clinically relevant in-
hibitors bortezomib, ixazomib, delanzomib, and oprozomib.[6]
The most important observations derived from Schrader
et al.’s study require us to revise our long-held (>15 years)
conception of the mechanism by which peptide epoxyketone
proteasome inhibitors react with the proteasome’s catalytic
threonine residues. Specifically, the cocrystal structures of the
human 20S proteasome with three different peptide epoxyke-
tone proteasome inhibitors—oprozomib (solved at 1.9 a reso-
lution), epoxomicin (solved at 2.4 a resolution), and dihydro-
eponemycin (solved at 2.0 a resolution)—reflected the forma-
tion of a seven-membered, 1,4-oxazepano adduct between the
inhibitor and the catalytic threonine residue within the b5
active site.[6] This finding diverges from the previously reported
formation of the 1,4-morpholino adduct and indicates that, in
the second step of the inhibitory reaction, the N-terminal
amino group of the proteasome’s catalytic threonine attacks
the b, rather than the a, carbon of the inhibitor’s epoxide (Fig-
ure 2).[3c, d, 5b, 6] Additional results led Schrader et al. to conclude
that the peptide ketoaldehyde inhibitor Z-LLY-ketoaldehyde
forms a 1,4-morpholino adduct with b5’s catalytic threonine
residue, contrasting the 5,6-dihydro-2H-1,4-oxazino ring prod-
uct proposed by Gr-wert et al.[6, 7]
Through cluster quantum chemical-calculations and kinetic
assays, Schrader et al. further evaluated the differences be-
tween the inhibitory reactions that form six-membered versus
seven-membered rings.[6] Based on the calculated pathways of
these reactions, they identified the cyclization step as the bot-
tleneck of both reactions. Their results also indicated that, al-
though the six-membered ring product is more thermodynam-
ically stable than the seven-membered ring product, the great-
er strain of the transition state of the former pathway causes
the latter pathway to be favored from a kinetic standpoint.
The results of kinetic assays also support the idea that seven-
membered ring formation is kinetically favored over six-mem-
bered ring formation.
The contributions of Schrader et al. provide important in-
sight for proteasome inhibitor design. Currently, the clinical de-
velopment of proteasome inhibitors remains limited to those
falling within the peptide boronic acid or peptide epoxyketone
classes, as they are regarded as having acceptably low activity
against non-proteasomal proteases. But these new findings
suggest the possibility that the so-far-unparalleled specificity
of the epoxyketone pharmacophore for the proteasome’s cata-
lytic threonine residues can be extended to other classes of
proteasome inhibitors yet to be developed. Importantly, they
indicate that the second electrophile of a dual-electrophilic
pharmacophore can be placed not one carbon, but two car-
bons, away from the first (i.e. , in the b position) so as to pro-
mote formation of the kinetically favored seven-membered
ring.[6] One might envision, for example, generating inhibitors
analogous to the peptide halomethyl ketone cysteine/serine
protease inhibitors, but in which the leaving group is attached
to the b instead of to the a carbon. Exploration of these possi-
bilities could yield inhibitors with improved proteasome selec-
tivity relative to peptide boronic acids and improved pharma-
cokinetic profiles over those of peptide epoxyketones. It is
hoped that such improvements would in turn lead to en-
Figure 2. New structural data revise our understanding of the reaction between the epoxyketone pharmacophore of an inhibitor and the catalytic threonine
residue of the proteasome. A) Illustration of oprozomib complexed with the b5 active site (left), with a close-up view of the seven-membered ring adduct
(right). Reprinted with permission from ref. [6] . Copyright : AAAS 2016. B) Previously proposed and newly revised reaction mechanisms.[5b, 6]
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hanced anticancer efficacy and reduced toxicity, thereby bene-
fiting patients with multiple myeloma as well as those with
other types of cancer.
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